Peter Roberts, MD | Authors

Evolution of Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer

July 02, 2000

A number of randomized clinical trials and meta-analyses now support the conclusion that combined modality regimens that include cisplatin (Platinol)-based chemotherapy improve survival in stage III non–small-cell lung